In contrast, satisfactory results were obtained in CNS tumors, where erlotinib therapy inhibited MB migration in vitro and successfully diminished the levels of phosphorylated EGFR in EPN models [587,588]. The gene discussed is EGFR; the disease is central nervous system neoplasm.